Dipartimento di Biologia Animale e dell'Uomo, Via Accademia Albertina, 13, Torino 10123, Italy.
Am J Physiol Heart Circ Physiol. 2010 Aug;299(2):H470-81. doi: 10.1152/ajpheart.00800.2009. Epub 2010 Jun 4.
Obestatin, a newly discovered peptide encoded by the ghrelin gene, induces the expression of genes regulating pancreatic beta-cell differentiation, insulin biosynthesis, and glucose metabolism. It also activates antiapoptotic signaling pathways such as phosphoinositide 3-kinase (PI3K) and ERK1/2 in pancreatic beta-cells and human islets. Since these kinases have been shown to protect against myocardial injury, we sought to investigate whether obestatin would exert cardioprotective effects. Both isolated perfused rat heart and cultured cardiomyocyte models of ischemia-reperfusion (I/R) were used to measure infarct size and cell apoptosis as end points of injury. The presence of specific obestatin receptors on cardiac cells as well as the signaling pathways underlying the obestatin effect were also studied. In the isolated heart, the addition of rat obestatin-(1-23) before ischemia reduced infarct size and contractile dysfunction in a concentration-dependent manner, whereas obestatin-(23-1), a synthetic analog with an inverse aminoacid sequence, was ineffective. The cardioprotective effect of obestatin-(1-23) was observed at concentrations of 10-50 nmol/l and was abolished by inhibiting PI3K or PKC by the addition of wortmannin (100 nmol/l) or chelerythrine, (5 micromol/l), respectively. In rat H9c2 cardiac cells or isolated ventricular myocytes subjected to I/R, 50 nmol/l obestatin-(1-23) reduced cardiomyocyte apoptosis and reduced caspase-3 activation; the antiapoptotic effect was blocked by the inhibition of PKC, PI3K, or ERK1/2 pathways. In keeping with these functional findings, radioreceptor binding results revealed the presence of specific high-affinity obestatin-binding sites, mainly localized on membranes of the ventricular myocardium and cardiomyocytes. Our data suggest that, by acting on specific receptors, obestatin-(1-23) activates PI3K, PKC-epsilon, PKC-delta, and ERK1/2 signaling and protects cardiac cells against myocardial injury and apoptosis induced by I/R.
胃泌酸调节素,一种新发现的由生长激素释放肽基因编码的肽,可诱导调节胰岛β细胞分化、胰岛素生物合成和葡萄糖代谢的基因表达。它还可激活胰岛β细胞和人胰岛中的抗凋亡信号通路,如磷脂酰肌醇 3-激酶(PI3K)和 ERK1/2。由于这些激酶已被证明可以防止心肌损伤,因此我们试图研究胃泌酸调节素是否具有心脏保护作用。我们使用分离的灌注大鼠心脏和培养的心肌细胞缺血再灌注(I/R)模型来测量损伤的终点,即梗死面积和细胞凋亡。还研究了心脏细胞上特定胃泌酸调节素受体的存在以及胃泌酸调节素作用的信号通路。在分离的心脏中,在缺血前添加大鼠胃泌酸调节素-(1-23)可浓度依赖性地减少梗死面积和收缩功能障碍,而具有反向氨基酸序列的合成类似物胃泌酸调节素-(23-1)则无效。胃泌酸调节素-(1-23)的心脏保护作用在 10-50 nmol/l 的浓度下观察到,并通过添加wortmannin(100 nmol/l)或 chelerythrine(5 μmol/l)分别抑制 PI3K 或 PKC 而被消除。在大鼠 H9c2 心肌细胞或分离的心室肌细胞 I/R 中,50 nmol/l 胃泌酸调节素-(1-23)减少心肌细胞凋亡并减少 caspase-3 激活;该抗凋亡作用被 PKC、PI3K 或 ERK1/2 通路的抑制所阻断。与这些功能发现一致,放射受体结合结果显示存在特异性高亲和力胃泌酸调节素结合位点,主要定位于心室心肌和心肌细胞的膜上。我们的数据表明,胃泌酸调节素-(1-23)通过作用于特定受体,激活 PI3K、PKC-epsilon、PKC-delta 和 ERK1/2 信号通路,保护心脏细胞免受 I/R 引起的心肌损伤和凋亡。